Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005807 · ClinicalTrials.gov registry record · Phase 1
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00005807 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT00005807, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metastatic or unresectable solid tumors.
Interventions
- DRUG BMS-247550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2000-07 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005807
The ClinicalTrials.gov registry entry for NCT00005807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-247550 is the first listed.
NCT00005807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005807 about?
NCT00005807 is a clinical study titled "Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metasta...
What is the current status of trial NCT00005807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2000-07. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00005807?
The interventions under investigation include: BMS-247550 (DRUG).
Who is sponsoring clinical trial NCT00005807?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.